Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
Samuel M. S. Cheng, Chris Ka Pun Mok, Yonna W. Y. Leung, Susanna S. Ng, Kaimin Chan, Fanny W.S. Ko, Chunke Chen, Karen Yiu, Bosco HS Lam, Eric H. Y. Lau, Ka Pang Chan, Leo L. H. Luk, John K. C. Li, Leo C. H. Tsang, Leo L. M. Poon, David S.C. Hui, Malik Peiris
Topics & Concepts
TiterVirologyHeterologousNeutralizing antibodyVaccinationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AntibodyVirusNeutralizationCoronavirus disease 2019 (COVID-19)Antibody responseMedicine2019-20 coronavirus outbreakBiologyImmunologyOutbreakInfectious disease (medical specialty)DiseaseGeneGeneticsPathologySARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingCOVID-19 Clinical Research Studies